Time-Dependent Risk of Fidelis Lead Failure

Faulknier, Brett; Traub, Darren; Aktaş, Mehmet K.; Aguila, Alian; Rosero, Spencer; Daubert, James P.; Hall, Burr; Shah, A M; Taylor, Sarah; McNitt, Scott; Moss, Arthur J.; Zaręba, Wojciech; Huang, David T.

doi:10.1016/j.amjcard.2009.08.655

Cited by 43 publications

(52 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the literature, there are slightly lower mortality rates in SF recipients [6]. The trends of this study show quite the same results as in the literature -in non-survivor groups, more frequent implantation was in secondary prevention [9,23] and in older ages [9] than in survivors. ICD interventions without preceding arrhythmic event also do not worsen clinical state of the patients just as Mehta et al [29] has reported.…”

Section: Mortalitysupporting

confidence: 78%

“…No single death could be categorized as associated with lead defect, which concurs with other studies [7,8,23,24,29]. In the literature, there are slightly lower mortality rates in SF recipients [6].…”

Section: Mortalitysupporting

confidence: 73%

Section: Lead Failurecontrasting

confidence: 57%

“…This study has not confirmed previous findings [21][22][23][24] that patients with confirmed SF lead fracture have statistically significantly higher LVEF, the results obtained herein present contrary results -in our population patients with dysfunctional lead had lower LVEF. Additionally, no statistically significant correlation has been found according to gender www.cardiologyjournal.org [7,9,12,25] or age at implantation [23]. Neither was any statistical correlation found between the type of prevention (primary vs. secondary), venous access [7,18,21,24,26,27] (cephalic vs. other), nor position of the lead tip in the right ventricle (apex vs. right ventricular outflow track).…”

Section: Lead Failurecontrasting

confidence: 57%

See 3 more Smart Citations

Sprint Fidelis implantable cardioverter-defibrillators lead patient management and survival: Single center study

et al. 2017

View full text Add to dashboard Cite

. Patients were subjected to regular check-ups in 3 to 6 month intervals. Results: Patients were implanted at a median age of 66.5 years and majority of them had ischemic cardiomyopathy (72%). A majority of the studied population were men (72.2%). Predominantly dual-chamber ICD (ICD-DR) were implanted (50% ICD-DR vs. 47.2% ICD-VR). The guidelines for management of patients implanted with SF were fully implemented. During the follow-up 14 (38.9%) patients died.No deaths were noted that could be attributed to lead failure. In 5 cases lead failure was identified and of these 4 leads were replaced. Median time from implantation to the detection of lead dysfunction was 52 months (IQR 49; 83) (Cardiol J 2017; 24, 3: 259-265)

show abstract

Section: Mortalitysupporting

confidence: 78%

Section: Mortalitysupporting

confidence: 73%

Section: Lead Failurecontrasting

confidence: 57%

Section: Lead Failurecontrasting

confidence: 57%

See 2 more Smart Citations

Sprint Fidelis implantable cardioverter-defibrillators lead patient management and survival: Single center study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…1 The manufacturer voluntarily removed Fidelis leads from the market in 2007 after 268 000 were implanted worldwide. 2 Subsequently, the Fidelis fracture rate was observed to accelerate during the first 2 years after implantation, [3][4][5] and leads in younger 6 more active patients with less impairment of left ventricular function appeared to be more prone to failure. 3 …”

mentioning

confidence: 99%